Literature DB >> 30569481

Safety profile of human papilloma virus vaccines: an analysis of the US Vaccine Adverse Event Reporting System from 2007 to 2017.

Giulia Bonaldo1, Alberto Vaccheri1, Ottavio D'Annibali1, Domenico Motola1.   

Abstract

AIMS: Human papilloma virus (HPV) is the cause of different types of carcinoma. Despite the remarkable effectiveness of the HPV vaccines, there have been many complaints about their risk-benefit profile due to adverse events following immunization (AEFI). The purpose of this study is to analyse the safety profile of the HPV vaccine basing on real-life data derived from reports of suspected AEFIs collected in the US Vaccine Adverse Events Reporting System (VAERS) and assess if the searches on Google overlap with spontaneous reporting.
METHODS: We collected all the reports in VAERS between January 2007 to December 2017 related to the HPV vaccines. A disproportionality analysis using reporting odds ratio (ROR) with 95% confidence interval was performed.
RESULTS: Over the 10-year period, 55 356 reports of AEFI related to HPV vaccines were retrieved in VAERS, corresponding to 224 863 vaccine-event pairs. The highest number of reports was related to Gardasil (n = 42 244). The two events more frequently reported and statistically significant for HPV vaccines were dizziness (n = 6259; ROR = 2.60; 95% confidence interval 2.53-2.66) and syncope (n = 6004; ROR = 6.28; 95% confidence interval 6.12-6.44). The trends of spontaneous reporting and Google searches overlap.
CONCLUSION: The AEFI analysis showed that the events most frequently reported were non-serious and listed in the corresponding summary of product characteristics. Potential safety signals arose regarding less frequent AEFIs that would deserve further investigation. It is extremely important to disseminate correct and evidence-based scientific information.
© 2018 The British Pharmacological Society.

Entities:  

Keywords:  adverse events following immunization; human papilloma virus; safety; vaccine; vaccine adverse event reporting system; vaccinovigilance

Mesh:

Substances:

Year:  2019        PMID: 30569481      PMCID: PMC6379209          DOI: 10.1111/bcp.13841

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  29 in total

Review 1.  Management of anogenital warts (condylomata acuminata).

Authors:  G von Krogh
Journal:  Eur J Dermatol       Date:  2001 Nov-Dec       Impact factor: 3.328

2.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.

Authors:  J M Walboomers; M V Jacobs; M M Manos; F X Bosch; J A Kummer; K V Shah; P J Snijders; J Peto; C J Meijer; N Muñoz
Journal:  J Pathol       Date:  1999-09       Impact factor: 7.996

Review 3.  The benefit of the doubt or doubts over benefits? A systematic literature review of perceived risks of vaccines in European populations.

Authors:  Emilie Karafillakis; Heidi J Larson
Journal:  Vaccine       Date:  2017-07-29       Impact factor: 3.641

4.  Global cancer statistics.

Authors:  Ahmedin Jemal; Freddie Bray; Melissa M Center; Jacques Ferlay; Elizabeth Ward; David Forman
Journal:  CA Cancer J Clin       Date:  2011-02-04       Impact factor: 508.702

5.  Anti-vaccine activists, Web 2.0, and the postmodern paradigm--an overview of tactics and tropes used online by the anti-vaccination movement.

Authors:  Anna Kata
Journal:  Vaccine       Date:  2011-12-13       Impact factor: 3.641

6.  Syncope after vaccination--United States, January 2005-July 2007.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2008-05-02       Impact factor: 17.586

7.  Telogen effluvium following bivalent human papillomavirus vaccine administration: a report of two cases.

Authors:  Marco Tuccori; Chiara Pisani; Laura Bachini; Milena Pardini; Stefania Mantarro; Luca Antonioli; Matteo Fornai; Marinella Rubinelli; Carlo Cirinei; Corrado Blandizzi
Journal:  Dermatology       Date:  2012-05-11       Impact factor: 5.366

8.  Safety of bivalent human papillomavirus vaccine in the US vaccine adverse event reporting system (VAERS), 2009-2017.

Authors:  Tiffany A Suragh; Paige Lewis; Jorge Arana; Adamma Mba-Jonas; Rongxia Li; Brock Stewart; Tom T Shimabukuro; Maria Cano
Journal:  Br J Clin Pharmacol       Date:  2018-09-21       Impact factor: 4.335

9.  Estimates of cancer burden in Italy.

Authors:  Silvia Rossi; Emanuele Crocetti; Riccardo Capocaccia; Gemma Gatta
Journal:  Tumori       Date:  2013 May-Jun

Review 10.  Safety of Human Papillomavirus 9-Valent Vaccine: A Meta-Analysis of Randomized Trials.

Authors:  Ana Paula Ferreira Costa; Ricardo Ney Oliveira Cobucci; Janine Medeiros da Silva; Paulo Henrique da Costa Lima; Paulo César Giraldo; Ana Katherine Gonçalves
Journal:  J Immunol Res       Date:  2017-07-24       Impact factor: 4.818

View more
  11 in total

1.  Safety profile of human papilloma virus vaccines: an analysis of the US Vaccine Adverse Event Reporting System from 2007 to 2017.

Authors:  Giulia Bonaldo; Alberto Vaccheri; Ottavio D'Annibali; Domenico Motola
Journal:  Br J Clin Pharmacol       Date:  2019-01-21       Impact factor: 4.335

2.  Adverse events reported for Mirena levonorgestrel-releasing intrauterine device in France and impact of media coverage.

Authors:  Claire Langlade; Amandine Gouverneur; Pauline Bosco-Lévy; Aurore Gouraud; Marie-Christine Pérault-Pochat; Johana Béné; Ghada Miremont-Salamé; Antoine Pariente
Journal:  Br J Clin Pharmacol       Date:  2019-07-31       Impact factor: 4.335

Review 3.  Pityriasis Lichenoides et Varioliformis Acuta Triggered by Human Papillomavirus Vaccine: A Case Report and Literature Review.

Authors:  Beata A Jastrząb; Aleksandra A Stefaniak; Anita Hryncewicz-Gwóźdź; Piotr Nockowski; Jacek C Szepietowski
Journal:  Acta Derm Venereol       Date:  2021-09-17       Impact factor: 3.875

4.  Trends in Human Papillomavirus Vaccine Safety Concerns and Adverse Event Reporting in the United States.

Authors:  Kalyani Sonawane; Yueh-Yun Lin; Haluk Damgacioglu; Yenan Zhu; Maria E Fernandez; Jane R Montealegre; Cecilia Ganduglia Cazaban; Ruosha Li; David R Lairson; Ying Lin; Anna R Giuliano; Ashish A Deshmukh
Journal:  JAMA Netw Open       Date:  2021-09-01

5.  Trends in reporting embolic and thrombotic events after COVID-19 vaccination: A retrospective, pharmacovigilance study.

Authors:  Yusuke Kan; Mizuho Asada; Yoshihiro Uesawa
Journal:  PLoS One       Date:  2022-08-01       Impact factor: 3.752

6.  Drug-Associated Parosmia: New Perspectives from the WHO Safety Database.

Authors:  Diane Merino; Alexandre Olivier Gérard; Susanne Thümmler; Nouha Ben Othman; Delphine Viard; Fanny Rocher; Alexandre Destere; Elise Katheryne Van Obberghen; Milou-Daniel Drici
Journal:  J Clin Med       Date:  2022-08-09       Impact factor: 4.964

7.  The characteristics and trend of adverse events following immunization reported by information system in Jiangsu province, China, 2015-2018.

Authors:  Ran Hu; Shanshan Peng; Yuanbao Liu; Fengyang Tang; Zhiguo Wang; Lei Zhang; Jun Gao; Hongxiong Guo
Journal:  BMC Public Health       Date:  2021-07-07       Impact factor: 3.295

8.  Evaluation of the safety profile of rotavirus vaccines: a pharmacovigilance analysis on American and European data.

Authors:  Giulia Bonaldo; Roberta Noseda; Alessandro Ceschi; Alberto Vaccheri; Domenico Motola
Journal:  Sci Rep       Date:  2020-08-12       Impact factor: 4.379

9.  Ten years of vaccinovigilance in Italy: an overview of the pharmacovigilance data from 2008 to 2017.

Authors:  F Moretti; L Gonella; S Gironi; A R Marra; C Santuccio; P Felicetti; F Petronzelli; P Marchione; S A Barnaba; A Poli; G Zanoni; U Moretti
Journal:  Sci Rep       Date:  2020-08-24       Impact factor: 4.379

10.  Change Point Analysis for Detecting Vaccine Safety Signals.

Authors:  Seung-Hun You; Eun Jin Jang; Myo-Song Kim; Min-Taek Lee; Ye-Jin Kang; Jae-Eun Lee; Joo-Hyeon Eom; Sun-Young Jung
Journal:  Vaccines (Basel)       Date:  2021-03-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.